Effect of king oyster mushroom (Pleurotus eryngii) on insulin resistance and dyslipidemia in db/db mice

Food Science and Biotechnology

Volumn 19, Issue 1, 2010, Pages 239-242

  Kim, Jung In ^a   Kang, Min Jung ^a   Im, Jieun ^a   Seo, Yeong Ju ^a   Lee, Young Min ^a   Song, Ji Hyun ^a   Lee, Jai Heon ^b   Kim, Mi Eun ^a  

^a Inje University   (South Korea)

^b Dong A University   (South Korea)

Author keywords

Diabetes mellitus; Dyslipidemia; Hyperglycemia; Insulin resistance; King oyster mushroom

Indexed keywords

BASIDIOMYCOTA; MUS; PLEUROTUS ERYNGII; PLEUROTUS OSTREATUS;

EID: 79957650792     PISSN: 12267708     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10068-010-0033-y     Document Type: Note

References (16)

1. Kahn SE. The relative contributions of insulin resistance and betacell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46: 3-19 (2003)
2. Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am. J. Med. 111: 633-642 (2001)
3. American Diabetes Association. Management of dyslipidemia in adults with diabetes (Position Statement). Diabetes Care 22: 56-59 (1999)
4. Kang TS, Kang MS, Sung JM, Kang AS, Shon HP, Lee SY. Effect of Pleurotus eryngii on the blood glucose and cholesterol in diabetic rats. Korean J. Mycol. 29: 86-90 (2001)
5. Kubo K, Aoki H, Nanba H. Anti-diabetic activity present in the fruit body of Grifola frondosa (maitake) I. Biol. Pharm. Bull. 17: 1106-1110 (1994)
6. Seto SW, Lam TY, Tam HL, Au ALS, Chan SW, Wu JH, Yu PHF, Leung GPH, Ngai SM, Yeung JHK, Leunge PS, Lee SMY, Kwan YW. Novel hypoglycemic effects of Ganoderma lucidum waterextract in obese/diabetic (+db/+db) mice. Phytomedicine 16: 426-436 (2009)
7. Kubo K, Nanba H. The effect of maitake mushrooms on liver and serum lipids. Altern. Ther. Health M. 2: 62-66 (1996)
8. Bobek P, Ozdin L, Kunjak L. Effect of oyster mushroom and isolated β-glucan on lipid peroxidation and on the activities of antioxidative enzymes in rats fed the cholesterol diet. J. Nutr. Biochem. 8: 469-471 (1997)
9. Kim MY, Seguin P, Kukahn J, Kim JJ, Chun SC, Kim EH, Seo SH, Kang EY, Kim SL, Park YJ, Ro HM, Chung IM. Phenolic compound concentration and antioxidant activities of edible and medicinal mushrooms from Korea. J. Agr. Food Chem. 56: 7265-7270 (2008)
10. Mori K, Kobayashi C, Tomita T, Inatomi S, Ikeda M. Antiatherosclerotic effect of the edible mushrooms Pleurotus eryngii (eringi), Grifola frondosa (maitake), and Hypsizygus marmoreus (bunashimeji) in apolipoprotein E-deficient mice. Nutr. Res. 28: 335-342 (2008)
11. th ed. Method 934.01, 942.05, 976.05, 954.02, 962.09. Association of Official Analytical Chemists, Gaithersburg, MD, USA (2000)
12. 1c by "high performance" cation-exchange chromatography. Clin. Chem. 26: 466-472 (1980)
13. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio heart study. Diabetes Care 20: 1087-1092 (1997)
14. Manohar V, Talpur N, Echard BW, Lieberman S, Preuss HG. Effects of a water soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice. Diabetes Obes. Metab. 4: 43-48 (2002)
15. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat. Clin. Pract. Endoc. 5: 150-159 (2009)
16. Gianturco S, Ramprasad M, Song R, Li R, Brown M, Bradley W. Apolipoprotein B48 or its apolipoprotein B100 equivalent mediates binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor. Arterioscl. Throm. Vas. 8: 968-976 (1998)